CSIMarket
 
Atricure Inc   (ATRC)
Other Ticker:  
 
 
Price: $32.1400 $-0.38 -1.169%
Day's High: $32.6565 Week Perf: -12.95 %
Day's Low: $ 31.38 30 Day Perf: -1.23 %
Volume (M): 675 52 Wk High: $ 59.61
Volume (M$): $ 21,685 52 Wk Avg: $41.79
Open: $32.26 52 Wk Low: $29.68



 Market Capitalization (Millions $) 1,482
 Shares Outstanding (Millions) 46
 Employees 850
 Revenues (TTM) (Millions $) 398
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) 26
 Capital Exp. (TTM) (Millions $) 42

Atricure Inc
Atricure Inc is a leading medical technology company that specializes in the development and commercialization of innovative devices that help surgeons around the world to perform better cardiac surgery procedures. The company's main focus is on the provision of advanced and minimally invasive surgical solutions that enhance patient outcomes and reduce healthcare costs.

Atricure was founded in 2000, and since then, it has become an industry leader in the field of electrophysiology, with a particular focus on the treatment of atrial fibrillation (AF). The company is headquartered in Mason, OH, and has a team of over 900 employees worldwide, including in Europe, Asia, and the Americas.

Atricure's product portfolio includes a range of advanced surgical devices and instruments that are used to treat various cardiac conditions. Some of the company's key products include the AtriCure CryoICE Cryoablation System, the AtriClip Left Atrial Appendage Management System, and the EPi-Sense Coagulation System.

The AtriCure CryoICE Cryoablation System is a minimally invasive system that delivers cold energy to the heart tissue to create a controlled lesion, which stops the abnormal electrical signals that can cause AF. The AtriClip Left Atrial Appendage Management System is designed to exclude the left atrial appendage from the circulation, reducing the risk of stroke in patients with AF.

The EPi-Sense Coagulation System is a bipolar radiofrequency energy device that helps surgeons safely create critically important lines of conduction block in the heart, which can help treat a range of cardiac abnormalities including AF.

Atricure is committed to innovation and product development, maintaining partnerships with leading researchers and medical institutions, and investing significant amounts in R&D every year. The company's culture is rooted in collaboration, integrity, passion, and excellence, and it places a significant emphasis on investing in employee development, diversity, and inclusion.

In conclusion, Atricure Inc is a leading medical technology company that has been at the forefront of innovation in the field of cardiac surgery. With a robust product portfolio, a strong commitment to R&D, and a culture of excellence, the company is well-positioned to achieve sustained growth and remain an industry leader in the years to come.


   Company Address: 7555 Innovation Way Mason 45040 OH
   Company Phone Number: 755-4100   Stock Exchange / Ticker: NASDAQ ATRC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Atricure Inc

Atricure Inc. Surges Ahead with Impressive Fourth Quarter Revenue Growth



The Medical Equipment & Supplies industry is witnessing substantial growth, and one company that has recently made headlines is Atricure Inc. Despite incurring a deficit per share in the fourth quarter of 2023, the company experienced a surge in revenue of 20.517% to $106.09 million compared to the same period the previous year. Atricure's impressive revenue growth surpasses its industry rivals, who only managed an overall 4.08% increase in revenue. Let's delve deeper into the financial performance of Atricure Inc and explore what these figures mean for investors.
Revenue Growth
Atricure Inc's revenue for the fourth quarter of 2023 showed a robust increase of 20.517% to $106.09 million, highlighting the company's strong market presence. In comparison, the Medical Equipment & Supplies industry experienced a more modest revenue growth of 4.08% in the same reporting period. This positive performance underlines Atricure's ability to outperform its competitors and capitalize on emerging opportunities within the sector.

Atricure Inc

Atricure Inc (ATRC) Shows Encouraging Growth in Q3 2023 Financials Despite Per-Share Loss

The stock market has always been a fascinating roller coaster ride for investors, and there are few things more thrilling than finding a hidden gem amidst all the chaos. As we delve into the financial third quarter of 2023, a particular company caught our attention - Atricure Inc (ATRC). Despite reporting a loss of $-0.20 per share, there is a multitude of positive insights to be gathered from their recent performance.
To understand the gravity of Atricure Inc's progress, let's take a look at their numbers compared to the previous year. In Q3 of 2022, their loss per share stood at $-0.27, indicating a remarkable improvement by $0.07. Furthermore, their shortfall surged from $-0.11 per share in the prior reporting period, showcasing an evident course correction.

Atricure Inc

Atricure Inc Records Significant Financial Growth in Q2 2023 with Impressive Rise in Revenue

As a stock market journalist, I've been keeping a close eye on Atricure Inc's financial results and the recent numbers have shown some positive developments for the company.
In terms of earnings per share, Atricure Inc has made significant progress. In the most recent fiscal period, the company managed to decrease their loss per share from $-0.32 to $-0.11 compared to the same period last year. Moreover, income per share improved from $-0.14 in the preceding quarter. These improvements indicate that Atricure Inc has been able to cut costs and increase their profit margins.

Atricure Inc

Despite the boost in revenue Profitability not Reached by in the first quarter of 2023 earnings season

ATRC Reports Surge in Revenue but Posts Loss
Atricure Inc (ATRC), a leading innovator in medical devices and technologies for the treatment of atrial fibrillation and valve repair and replacement, recently reported a surge in revenue in its Mar 31 2023 report. The report indicated a revenue increase of 25.367% to $93.49 million from the same reporting period a year before. This indication comes as a good sign for the company especially given the difficult supply side of things. Despite an increase in revenue, the company had an advanced shortfall of $-0.14 per share, in comparison to the preceding period when the shortfall was $-0.09 per share. Additionally, in the first quarter of the 2023 earnings season, ATRC reported a net shortfall of $-6.476 million which is a stark contrast from the deficit of $-15.183 million in the same reporting period a year ago.
Atricure, like any company, is focused on delivering shareholder value over the short and long term. While the company is dealing with difficult supply side challenges, the business climate for their proposals remains healthy. The company is therefore focused on handling these conditions in order to match commitments and achieve their long-term market targets. The company is expected to report its next financial results on August 02, 2023.






 

Atricure Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Atricure Inc does not provide revenue guidance.

Earnings Outlook
Atricure Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com